Leyden Labs raised $20M in funding, led by the European Investment Bank, to expand operations and enhance R&D efforts.

Jun 04, 2025•3 months ago

Amount Raised

$20 Million

LeidenBiotechnology

Investors

European Investment Bank

Description

Leyden Labs, a Leiden, the Netherlands-based clinical-stage biotechnology company, raised $20M in funding. The round was led by the European Investment Bank. The company intends to use the funds to expand operations and its R&D efforts. Led by CEO Koenraad Wiedhaup, Leyden Labs is developing therapies to treat respiratory viruses.

Company Information

Company

Leyden Labs

Location

Leiden, South Holland, Netherlands

About

Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families. The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech